Allurion Technologies, Inc., a leading innovator in weight management solutions, recently presented four abstracts at the European Congress on Obesity (ECO) held in Malaga, Spain, from May 11-14, 2025. The presentations focused on the effectiveness and transformative impact of the Allurion Gastric Balloon and the Virtual Care Suite (VCS), an AI-powered digital platform, in optimizing weight loss outcomes and preserving lean body mass. One study involved 138 patients prescribed GLP-1s (glucagon-like peptide-1 receptor agonists) with a normal dose escalation who utilized the VCS. Over four months, these patients experienced an average increase of 6.1% in lean body mass, a 6.4% increase in muscle mass, and a 10.2% decrease in fat mass. The data suggests that Allurion's AI-driven behavioral support can significantly assist patients in maintaining muscle mass, even when using higher doses of GLP-1 medications, which typically lead to muscle loss. Another study examined the efficacy of combining the Allurion Gastric Balloon with semaglutide, a type of GLP-1 medication. This combination therapy was tested on 60 patients, resulting in an average reduction of 21.2% in total body weight over a 10-month period. Notably, the patients also saw improvements in metabolic parameters, comparable to those achieved through bariatric surgery. According to Dr. Roberta Ienca, who oversaw the study at the Nuova Villa Claudia Clinic in Rome, the Allurion Program and semaglutide represent a significant advancement in weight loss management. She highlighted the potential for this approach to provide a more sustainable path to achieving and maintaining a healthier weight, particularly for patients with severe obesity who seek alternatives to surgical procedures. A third study evaluated the weight loss outcomes of 43 patients prescribed GLP-1s and using the VCS over nine months. These patients achieved an average weight reduction of 17.3%, surpassing the results observed in US studies where the VCS was not employed. Specifically, US studies reported an average weight loss of 15.2% with tirzepatide and 7.9% with semaglutide, both at 12 months. The findings underscore the potential of AI-driven interventions in enhancing traditional weight loss methods. The fourth study was a large single-center experience involving 2,000 patients treated with the Allurion Program between 2017 and 2024. The participants achieved an average weight reduction of 12.4% after four months and an average increase of 9.8% in muscle mass after six months. These results indicate that the Allurion Program can be safe, effective, and scalable for obesity clinics, contributing to better overall health outcomes for patients. The abstracts included detailed presentations on the following topics: Optimizing Body Composition and Lean Mass Preservation: The Value of AI-Powered Digital Platforms and Health Coaches for Patients on GLP-1 Medications - Presented by Bill Nadeau, RD, Vice President of Medical Affairs at Allurion, this study highlighted the role of AI in helping patients maintain muscle mass while undergoing GLP-1 therapy. The New Era of Combination Weight Loss Treatments: The Swallowable Gastric Balloon Program and the Anti-Obesity Medication Semaglutide - Dr. Roberta Ienca presented the findings on the effectiveness of combining the Allurion Gastric Balloon with semaglutide, emphasizing the potential benefits of this combined approach. Enhancing Weight Loss Outcomes with GLP-1 Medications: The Role of AI-Powered Digital Platforms and Health Coaches - Another presentation by Bill Nadeau focused on the improved weight loss outcomes achieved through the integration of AI and health coaching in GLP-1 treatment regimens. Exceptional Outcomes and Safety Profile in the First 2,000 Patients Treated with the Allurion Balloon Program at a Single Spanish Bariatric Center - Dr. Adelardo Caballero from the Instituto de Obesidad in Madrid, Spain, discussed the safety and effectiveness of the Allurion Balloon Program, showcasing the potential for widespread adoption in clinical settings. Industry insiders have hailed the Allurion Program as a game-changer in the field of weight management. By integrating AI and digital health coaching, Allurion is addressing some of the key challenges in obesity treatment, such as patient adherence and muscle preservation. The company's unique approach not only enhances weight loss outcomes but also offers a non-invasive and scalable solution for obesity clinics. Allurion Technologies, listed on the NYSE under the ticker symbol ALUR, is committed to advancing metabolically healthy weight loss through innovative, patient-centric technologies and programs. For more information, visit www.allurion.com. The positive outcomes from these studies position Allurion as a leader in the development of combination weight loss treatments and AI-driven virtual care solutions. However, the company must still navigate regulatory approvals and market acceptance, along with potential geopolitical and economic uncertainties that could impact its growth. Despite these challenges, Allurion's forward-looking strategies and robust clinical data provide a strong foundation for its continued innovation and success in the highly competitive weight management market.